| 摘要 |
PURPOSE: The method for treating polycystic kidney disease is provided, which includes administering TNF-alpha or an agent which stimulates TNF-alpha production in vivo. CONSTITUTION: TNF-alpha or an agent which stimulates TNF-alpha production is administered in a pharmacologically acceptable carrier, excipient or diluent by intravenous, intraperitoneal, intraarterial, subcutaneous, oral or intramuscular routes. Such agents include indomethacin, naproxen, and ibuprofen. TNF-alpha for parenteral administration can be in the form of a sterile injectable preparation, like a sterile injectable aqueous or oleaginous suspension formulated using dispersing or wetting agents and suspending agents. This treatment is repeated every 2 or 3 days until the cystic disease, like breast cysts, bronchogenic cysts, choledochal cysts, colloidal cysts, congenital cysts, and polycystic kidney disease is improved.
|
